MKK7-COV-9 (MKK7 Covalen inhibitor 9) is a potent, selective, covalent MKK7 (MAP2K7) inhibitor, displays >1,000-fold selectivity over MKK4.
MKK7-COV-9 displays remarkable selectivity against a kinome panel of 76 kinases.
MKK7-COV-9 inhibits the CD86+ response in primary mouse B cells in response to LPS stimulation (EC50=4.9 uM).
MKK7-COV-9 has half-lives >40 min in dog and rat, and significantly improved stability in human and monkey liver microsomes.
MKK7-COV-9 is not cytotoxic to a panel of human cell lines.
